Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 250-261

  Wang, Bing ^a   Liang, Meina ^a   Yao, Zhenling ^a   Vainshtein, Inna ^a   Lee, Rozanne ^a   Schneider, Amy ^a   Zusmanovich, Mikhail ^a   Jin, Feng ^a   O'Connor, Kamille ^a   Donato Weinstein, Bettina ^a   Iciek, Laurie ^a   Lavallee, Theresa ^a   Roskos, Lorin ^a  

^a MEDIMMUNE   (United States)

Author keywords

B lymphocyte lifespan; Bioequivalence; Biotechnology; CAT 8015; Comparability; Moxetumomab pasudotox; Pharmacodynamics; Pharmacokinetics; Population pharmacokinetics pharmacodynamics

Indexed keywords

CD22 ANTIGEN; MOXETUMOMAB PASUDOTOX;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BODY WEIGHT; BONE MARROW; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; EXPERIMENTAL MONKEY; IMMUNOGENICITY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAXIMUM PLASMA CONCENTRATION; NEGATIVE FEEDBACK; NONHUMAN;

EID: 84870702138     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23343     Document Type: Article

References (25)

1. Putnam W, Prabhu S, Zheng Y, Subramanyam M, Wang Y. 2009. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28:509-516.
2. European Medicines Agency. 2007. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process, non-clinical and clinical issues. London, UK: EMA.
3. Food and Drug Administration. 1996. Guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Silver Spring, Maryland: FDA.
4. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. 2007. Immunotoxin treatment of cancer. Annu Rev Med 58:221-237.
5. Wilson GL, Fox CH, Fauci AS, Kehrl JH. 1991. cDNA cloning of the B cell membrane protein CD22: A mediator of B-B cell interactions. J Exp Med 173:137-146.
6. Shan D, Press OW. 1995. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466-4475.
7. Cesano A, Gayko U. 2003. CD22 as a target for passive immunotherapy. Semin Oncol 30:253-257.
8. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, DiRenzo N, Carotenuto N. 2000. Quantitative flow cytometry for the differential diagnosis of leukemic B cell chronic lymphoproliferative disorders. Am J Hematol 64:275-281.
9. Tedder TF, Tuscano J, Sato S, Kehrl JH. 1997. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481-504.
10. Kreitman RJ, Pastan I. 2011. Antibody fusion protein: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 17:6398-6405.
11. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. 2002. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 8:995-1002.
12. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, Peschel C, Licht T. 2004. Induction of caspase-dependent programmed cell death in B cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 103:2718-2726.
13. Alderson RF, Escandon E, Chen T, Yeung P, Hodges D, Geng W, Fitzgerald DJP, Kreitman RJ, Pastan I, Fox JA. 2006. Characterization of CAT-8015: A pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies. Proc Amer Assoc Cancer Res 47:3728.
14. Wayne A, Kreitman R, Pastan I. 2007. Monoclonal antibodies and immunotoxins as new therapeutic agents for childhood acute lymphoblastic leukemia. Pediatric Cancer. 2007 Educational Book. Alexandria, VA: ASCO 596-601.
15. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Lechleider R, Pastan I. 2012. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822-1828.
16. Holford N. 2005. The visual predictive check superiority to standard diagnostic (rorschach) plots. Pamplona, Spain: Population Approach Group Europe Annual Conference.
17. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495.
18. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257.
19. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W. 2000. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95:2514-2522.
20. Roskos L, Lum P, Lockbaum P, Schwab G, Yang B. 2006. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 46:747-757.
21. Agoram B, Heatherington AC, Gastonguay MR. 2006. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8:E552-E563.
22. Roskos LK, Ren S, Robbie G. 2011. Application of modeling and simulation in the development of protein drugs. In Clinical trial simulations: Applications and trends; Kimko HC, Peck CC, Eds. 1st ed. New York City, New York: Springer, pp 365-400.
23. Krzyzanski W. 2011. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn 38:179-204.
24. Fulcher DA, Basten A. 1997. B cell life span: A review. Immunol Cell Biol 75:446-455.
25. De Boer R, Mohri H, Ho D, Perelson A. 2006. Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency cirus-infected and uninfected rhesus macaques. J Immunol 170:2479-2487.